CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback